We invite you to surf through the different sections of this page, where you can find all the important topics related to your participation at the ESMO Sarcoma and Rare Cancers Congress 2025.
Industry Guidelines
To get up to speed with your preparation for the ESMO Sarcoma and Rare Cancers Congress 2025, please download our Industry Guidelines below.
Download the ESMO Sarcoma and Rare Cancers Congress 2025 Industry Guidelines
Other relevant information will be added to this page and don’t forget to bookmark us for easy access.
Third-party media activities
Media activities initiated by third parties during or in connection with the ESMO Sarcoma and Rare Cancers Congress 2025, including, but not limited to:
- Meetings such as press conferences, media briefings, educational sessions for media representatives, as well as
- PR activities, such as press releases, news, articles, interviews, etc.
are subject to the ESMO Policy on Third-Party Media Activities. This policy aims to guarantee proper and correct distribution of oncology and cancer-related information to media representatives in connection with the conference.
Press events in or outside the congress centre but concomitant with/or during breaks of the scientific programme of the ESMO Sarcoma and Rare Cancers Congress 2025 are subject to ESMO Press Office approval. Please contact media@esmo.org
Compliance Information
ESMO Sarcoma and Rare Cancers Congress 2025 is organised by the European Society of Medical Oncology (based in Lugano, Switzerland). The Congress is provided to international HCPs with a majority from Europe and is following the EFPIA guidance/code.
EFPIA accreditation
The EFPIA accreditation submission has been taken care by ESMO, as ESMO is the content owner and organizer of the ESMO Sarcoma and Rare Cancers Congress 2025. Please do not submit any accreditation request to EFPIA on behalf of ESMO.
ESMO Sarcoma and Rare Cancers Congress 2025 submission has been assigned with the reference number EMT-24-00495 and the current status of the event is “Under Review”. You can see and follow the submission status here.
Should you have any queries or doubts on the EFPIA accreditation for ESMO Sarcoma and Rare Cancers Congress 2025 do not hesitate to contact meetings@esmo.org.
Official Italian agency for AIFA procedure
AIFA rules are mandatory only for Italian Pharmaceutical Companies that will attend a congress abroad.
Any pharmaceutical company supporting or participating in a congress, is subjected to an authorisation by AIFA (Italian Drug Agency), according to an Italian Government Decree (Decreto Legislativo 219/06 – art. 124). The request of authorisation must be submitted within 60 days before the starting date of the event.
ESMO advises pharmaceutical companies to contact the Official Agency:
AIM Group International – AIM Education S.r.l.
Contact: Cristina Ghidoli
Via G. Ripamonti, 129
20141 Milan – Italy
Tel.: +39 02 56601 1
Fax.: +39 02 70048585
E-mail: aifa@aimgroup.eu